Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Cognitive effects of nicotine.

Rezvani AH, Levin ED.

Biol Psychiatry. 2001 Feb 1;49(3):258-67. Review.

PMID:
11230877
2.

Development of nicotinic drug therapy for cognitive disorders.

Levin ED, Rezvani AH.

Eur J Pharmacol. 2000 Mar 30;393(1-3):141-6.

PMID:
10771007
3.

Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification, and anatomic localization.

Levin ED, McClernon FJ, Rezvani AH.

Psychopharmacology (Berl). 2006 Mar;184(3-4):523-39. Epub 2005 Oct 12. Review.

PMID:
16220335
4.

Nicotinic treatment for cognitive dysfunction.

Levin ED, Rezvani AH.

Curr Drug Targets CNS Neurol Disord. 2002 Aug;1(4):423-31. Review.

PMID:
12769614
5.

Nicotinic receptor subtypes and cognitive function.

Levin ED.

J Neurobiol. 2002 Dec;53(4):633-40. Review.

6.

Nicotinic-antipsychotic drug interactions and cognitive function.

Levin ED, Rezvani AH.

EXS. 2006;98:185-205. Review.

PMID:
17019889
7.

Nicotinic systems and cognitive function.

Levin ED.

Psychopharmacology (Berl). 1992;108(4):417-31.

PMID:
1357713
8.

Selective nicotinic acetylcholine receptor agonists: potential therapies for neuropsychiatric disorders with cognitive dysfunction.

Cincotta SL, Yorek MS, Moschak TM, Lewis SR, Rodefer JS.

Curr Opin Investig Drugs. 2008 Jan;9(1):47-56. Review.

PMID:
18183531
9.

Chronic inhibition of alpha4beta2 nicotinic receptors in the ventral hippocampus of rats: impacts on memory and nicotine response.

Arthur D, Levin ED.

Psychopharmacology (Berl). 2002 Mar;160(2):140-5. Epub 2001 Dec 20.

PMID:
11875631
10.

Nicotinic acetylcholine involvement in cognitive function in animals.

Levin ED, Simon BB.

Psychopharmacology (Berl). 1998 Aug;138(3-4):217-30. Review.

PMID:
9725745
11.

Four-week nicotine skin patch treatment effects on cognitive performance in Alzheimer's disease.

White HK, Levin ED.

Psychopharmacology (Berl). 1999 Apr;143(2):158-65.

PMID:
10326778
13.

Nicotinic systems in central nervous systems disease: degenerative disorders and beyond.

Newhouse PA, Kelton M.

Pharm Acta Helv. 2000 Mar;74(2-3):91-101. Review.

PMID:
10812945
14.

Treating the cognitive deficits of schizophrenia with alpha4beta2 neuronal nicotinic receptor agonists.

Radek RJ, Kohlhaas KL, Rueter LE, Mohler EG.

Curr Pharm Des. 2010 Jan;16(3):309-22. Review.

PMID:
20109141
15.

Neuronal nicotinic receptor and psychiatric disorders: functional and behavioral effects of nicotine.

Araki H, Suemaru K, Gomita Y.

Jpn J Pharmacol. 2002 Feb;88(2):133-8. Review.

16.

Nicotinic system involvement in Alzheimer's and Parkinson's diseases. Implications for therapeutics.

Newhouse PA, Potter A, Levin ED.

Drugs Aging. 1997 Sep;11(3):206-28. Review.

PMID:
9303280
17.

Nicotine and brain disorders.

Mihailescu S, Drucker-Colín R.

Acta Pharmacol Sin. 2000 Feb;21(2):97-104. Review.

18.

α7-Nicotinic receptors and cognition.

Levin ED.

Curr Drug Targets. 2012 May;13(5):602-6. Review.

PMID:
22300026
19.

Cognitive improvement by activation of alpha7 nicotinic acetylcholine receptors: from animal models to human pathophysiology.

Thomsen MS, Hansen HH, Timmerman DB, Mikkelsen JD.

Curr Pharm Des. 2010 Jan;16(3):323-43. Review.

PMID:
20109142
20.

Diversity and variability of the effects of nicotine on different cortical regions of the brain - therapeutic and toxicological implications.

Toledano A, Alvarez MI, Toledano-Díaz A.

Cent Nerv Syst Agents Med Chem. 2010 Sep 1;10(3):180-206. Review.

PMID:
20528766

Supplemental Content

Support Center